About this trial
Patients with traumatic spinal cord injury (tSCI) often suffer from spinal cord swelling inside the thecal sac, which contains the spinal cord and surrounding fluid, leading to increased pressure on the spinal cord tissue and decreased spinal cord blood flow at the site of injury. The combination of increased pressure and decreased blood flow causes vascular hypoperfusion of the spinal cord and exacerbates the severity of injury. This is also referred to as secondary injury. Thus, knowledge of spinal cord hypoperfusion would allow the treating physician to optimize the hemodynamic condition of the patient with acute spinal cord injury and potentially improve functional outcomes.
Eligibility criteria
Qualifiers
18 years of age minimum
Acute spinal cord injury fpr less than 24 hours
Injury ranging from mild spinal cord injury where motor function is preserved (AIS A) to complete injury where there is no motor or sensory function below the leel of the injury (AIS D)
Medically stable to undergo routine dorsal decompression, spinal realignment
Disqualifiers
Younger than 18 years old
Neurological lower extremity exam missing or intact
Traumatic head injury with a Glasgow score of 11 or lower
Cord injury level caudal to T10 (thoracic spine level 10)
Trial design
Treatments tested in this trial
- Perflutren lipid
Treatment groups
Sponsors and collaborators
University of Washington
Lead sponsor
United States Department of Defense
Collaborator